SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$FUUU is a Solana-based memecoin that was launched on http://Pump.fun in March 2024. The project is themed around the Rage Guy character, a figure that originated in the rage comic era of the late 2000s and became widely recognized across internet culture. Following the launch, the original developer discontinued involvement with the token. At that point, the CTO team assumed responsibility for coordinating ongoing community efforts around the project.  The stated purpose of $FUUU is cultural rather than financial. It is designed as a “culture coin” that highlights Rage Guy as a symbolic and relatable figure. The character’s expression of frustration, commonly represented by the text “FFFFUUUU,” reflects emotions that are often tied to both cryptocurrency markets and everyday experiences. By building a token around this meme, the project aims to preserve a recognizable piece of internet history within a blockchain context.  Unlike projects that emphasize detailed roadmaps, technical milestones, or defined utility, $FUUU positions itself as a lighthearted and entertainment-driven token. There are no team allocations, no taxes, and no embedded promises of profit or financial return. The coin is intended solely for cultural engagement, community participation, and meme creation. Holders and community members are encouraged to contribute through content, discussion, and the continued use of Rage Guy imagery, but there are no obligations or formal expectations tied to the token.  The CTO team provides organizational support, and back end support such as hiring an artist and creatin websites, the community drives activity associated with the project. This includes creating and sharing memes, maintaining discussion channels, and ensuring the Rage Guy character remains present in contemporary internet culture. The project does not claim utility beyond its role as a culture coin, and its sustainability depends entirely on voluntary participation and ongoing community interest.  From a transparency standpoint, the on-chain parameters of the token are publicly visible. These include the mint authority status, freeze authority, liquidity details (whether burned or locked), and circulating supply information. Any locked or burn addresses are disclosed for the purpose of supporting accurate supply tracking on external platforms.  Rage Guy ($FUUU) should not be viewed as an investment. The token has no intrinsic value and provides no rights, revenue, or guarantees to holders. As with all cryptoassets, trading is highly risky, and participants are advised to conduct their own research and fully understand the risks involved. The project’s focus remains cultural preservation and community expression rather than financial

FUUUUUUUUUUUUUU

Investors are fueling intense volatility in FUUU as the community leans into its role as a high-risk, speculative meme asset that embodies a collective protest against current market conditions. While some participants dismiss the project as a potential rug pull or scam, others are actively accumulating positions in hopes of capturing explosive upward price momentum.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending following a binding agreement to deploy high-performance GPU infrastructure for Yotta Data Services in India, a deal projected to generate significant multi-year revenue. While bullish investors view the contract as institutional validation and a catalyst for long-term growth, the community remains actively divided as skeptics point to historical price declines, ongoing concerns over share dilution, and the need for greater transparency regarding operational execution.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is experiencing intense market volatility and high trading volume following an earnings report that exceeded top-line expectations, fueling significant retail momentum and aggressive short-squeeze activity. While bullish investors point to strategic acquisitions and defense-sector contracts as evidence of long-term commercial scalability, the community remains deeply divided, with many actively debating the stock's valuation, heavy short interest, and the sustainability of its growth-by-acquisition strategy.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

United Airlines is seeing increased market attention following news that the government has signed an order to pay TSA agents, providing critical operational relief and easing fears of extended airport disruptions. The community is actively discussing the stock's potential for upside based on strong recent option activity, robust holiday travel demand, and the carrier's successful labor negotiations with flight attendants.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is trending as investors weigh its unique body-composition-focused obesity candidate, WVE-007, against the broader incretin market, with the community actively debating the durability and clinical efficacy of its muscle-sparing RNA interference platform following recent trial updates.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X Shares

LABU is currently trending as biotech investors capitalize on aggressive market rotation and increased speculative interest fueled by anticipation of further rate cuts and sector-specific buyout activity. Market participants are actively debating whether this rapid momentum represents a sustainable breakout or an overextended rally, leading to high-volume trading and significant volatility in leveraged biotech instruments.

FS KKR Capital Corp. is an externally managed, non-diversified, and closed-end management investment company that has been elected to be regulated as a business development company. Its portfolio includes FS Investments and KKR Credit. The company was founded by Michael Craig Forman on December 21, 2007 and is headquartered in Philadelphia, PA.

FS KKR Capital Corp

FS KKR Capital is facing significant selling pressure as investors grapple with a substantial distribution cut and concerns over the company's software-heavy portfolio exposure, leading to discussions about potential further downside to NAV. While some bargain hunters are attempting to build positions at multi-year lows, the prevailing sentiment remains bearish with traders actively buying put options to hedge against the ongoing credit cycle uncertainty.

General Mills, Inc. engages in the manufacture and marketing of branded consumer foods sold through retail stores. Its product categories include snacks, ready-to-eat cereal, convenient meals, pet food, refrigerated and frozen dough, baking mixes and ingredients, yogurt, and ice cream. It operates through the following segments: North America Retail, International, North America Pet, and North America Foodservice. The North America Retail segment includes grocery stores, mass merchandisers, membership stores, natural food chains, drug, dollar and discount chains, convenience stores, and e-commerce grocery providers. The International segment refers to the retail and foodservice businesses outside of the US and Canada. The North America Pet segment includes pet food products sold in national pet superstore chains, e-commerce retailers, grocery stores, regional pet store chains, mass merchandisers, and veterinary clinics and hospitals. The North America Foodservice segment offers ready-to-eat cereals, snacks, refrigerated yogurt, frozen meals, unbaked and fully baked frozen dough products, baking mixes, and bakery flour. The company was founded by Cadwallader C. Washburn on June 20, 1928 and is headquartered in Minneapolis, MN.

General Mills, Inc.

General Mills is currently trending as investors debate its valuation near multi-year lows, weighing a strong dividend yield against ongoing pressure from changing consumer habits, increased reliance on private-label brands, and the broader impact of weight-loss drugs on snacking behavior. While many in the community view the stock as a contrarian defensive play priced for a worst-case scenario, sentiment remains divided between those expecting a rebound due to institutional value-buying and those concerned that the packaged food sector faces structural headwinds.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is currently experiencing significant downward price pressure and low trading volume, as investors wait for tangible evidence of Yartemlea's sales ramp following its FDA approval. The community is actively debating the impact of institutional shorting and option pinning while expressing strong conviction in the stock's long-term valuation based on the Novo Nordisk partnership and upcoming European regulatory milestones.

Blacksky Technology, Inc. is a space-based intelligence company, which engages in the business of delivering real-time imagery, analytics, and high-frequency monitoring of most critical and strategic locations, economic assets, and events. The firm is also involved in providing geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operation of satellite and ground systems to government and commercial customers. The company was founded in 2014 and is headquartered in Herndon, VA.

BlackSky Technology Inc - Ordinary Shares - Class A

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials

Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials PR...

<ul class="summary-bullets"><li>OSR Holdings has until Aug. 31, 2026, to maintain a closing share price of at least $1 for ten consecutive business days.</li><li>Unit Vaximm immuno-oncology asset is pursuing a global licensing deal immuno-oncology asset that could include a $30 million upfront payment and $815 million in milestones.</li><li>OSR said that it is progressing with the planned merger of its units, RMC and Woori IO.</li></ul>Shares of OSR Holdings, Inc. (OSRH) surged more than 20% on Thursday after the company announced that it received an additional 180-day extension from Nasdaq to regain compliance with the exchange’s minimum bid price requirement.On a closing basis, <a href="https://stocktwits.com/symbol/OSRH">OSRH stock</a> is on track to record its biggest intra-day gains so far this year.Nasdaq initially notified OSR Holdings on Sept. 9, 2025, that it was not in compliance with the exchange’s $1 minimum bid price rule after its shares had traded below that level from August 25. OSR was given till March 4, 2026, to regain compliance.The company now has until Aug. 31, 2026, to meet the rule by maintaining a closing share price of at least $1 for ten consecutive business days. OSR noted that there is no immediate impact on the listing or trading of its stock.“We view this extension as a clear operational runway for our strategic initiatives to mature and translate into tangible shareholder value. With multiple near-term catalysts advancing, we believe OSR Holdings is well positioned to strengthen its capital markets profile and return to compliance through disciplined execution,” said Tim Smith, Head of Investor Relations.<h2 class="st-heading-2">Vaximm’s Potential Global Licensing Deal Could Fetch $815 Million</h2>Meanwhile, the company said it remains focused on several strategic initiatives. Its unit Vaximm is working toward a potential global licensing deal for its immuno-oncology asset VXM01, which could include $30 million upfront and up to $815 million in milestone payments.OSR is also progressing with the planned merger of its units, RMC and Woori IO, to build an integrated medical technology and distribution platform, while exploring global partnerships for Woori IO’s non-invasive glucose monitoring technology.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high message volumes.One user expects the stock to reach $10 in the short term.<stembedurl>https://stocktwits.com/JJBurch/message/646695066</stembedurl>The stock has shed around 15% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did OSRH Stock Jump 20% Today?

The company received an additional 180-day extension from Nasdaq to regain compliance after receiving an initial notice on Sept. 9, 2025.

Equity

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical...

Vaximm Appoints Sbastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Vaximm Appoints Sbastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform Vaximm Appoints Sbastien Wieckowski, PhD, as Chief Scientific Officer to...

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones Vaximm, an OSR Company, Receives Binding Term...

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings PR...

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period...

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 PR Newswire BELLEVUE, Wash., Dec. 1, 2025...

Cancer Immunotherapy Microcap Soars on Possible Major Licensing Deal

As pharmaceutical giants increasingly look outside their walls for breakthrough innovations, the licensing model has become the preferred pathway for bringing next-generation therapies to market. Biotech companies with promising platforms are commanding substantial upfront payments and milestone structures that can exceed $800 million, reflecting the pharmaceutical industry's appetite for differentiated assets that address significant unmet medical needs in oncology.Shares of OSR Holdings, Inc. (<a href="https://www.allpennystocks.com/stockquote/osrh" target="_blank">NASDAQ: OSRH</a>) are surging Friday after the company announced that its subsidiary Vaximm AG has entered a non-binding term sheet with BCM Europe AG for a potential exclusive global licensing agreement covering VXM01, Vaximm's first-in-class oral cancer immunotherapy platform.The proposed deal structure outlines significant financial terms that underscore the asset's commercial potential. Vaximm would receive a $20 million upfront payment upon execution of a definitive agreement, followed by up to $815 million in clinical, regulatory, and commercial milestone payments as the program advances through development and commercialization. Additionally, Vaximm would receive a pass-through of commercial royalties that BCME may collect from any future pharmaceutical partner, structured with a defined delta-recovery mechanism that allows BCME to recoup milestone differentials before royalty sharing commences.The term sheet establishes a six-month exclusivity period during which both parties will work toward finalizing a definitive licensing agreement, subject to customary due diligence and board approvals. Under the contemplated framework, BCME would function as a strategic financial intermediary, providing capital to fund the partnering and development activities necessary to secure a global out-license with a major pharmaceutical company. This approach mirrors structured financing models deployed by specialized life sciences investors including Royalty Pharma, Blackstone Life Sciences, and RTW Investments.According to Andreas Niethammer, incoming CEO of Vaximm AG, the term sheet represents an important milestone for advancing VXM01's development and global commercialization while allowing Vaximm to retain full ownership of its intellectual property. The structure enables the company to continue its mission of delivering innovative immunotherapies to patients worldwide with reduced dilution risk.Tim Smith, Head of Investor Relations at OSR Holdings, emphasized that Vaximm's oral T-cell platform represents a genuinely innovative approach in oncology with potential to transform cancer treatment. The exclusivity period with BCME reflects shared commitment to maximizing the global opportunity for VXM01, positioning the asset for a major pharmaceutical partnership that could unlock its full commercial potential.The term sheet also incorporates an optional blockchain-based royalty participation mechanism utilizing "TAC" tokens as an on-chain representation of future royalty revenue streams. Should Vaximm elect to draw development capital from the BCM Royalty Fund, a portion of VXM01 commercial royalties could be allocated to TAC token holders. If this option is not exercised, royalties would flow exclusively through the BCME pass-through structure.Vaximm's VXM01 platform employs a proprietary oral T-cell vaccination approach using live, attenuated bacterial vectors to deliver tumor-associated antigens and induce robust cellular immune responses. The lead candidate targets VEGFR-2 and has demonstrated clinical activity and safety across multiple cancer indications. BCME, a Switzerland-based life sciences investment entity, is currently OSR Holdings' largest shareholder.Shares of OSRH are up 25.8% at $0.57 in Friday afternoon trading. Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.View <a href='https://www.allpennystocks.com/specialreportsUS/4014/cancer-immunotherapy-microcap-soars-on-possible-major-licensing-deal'>more of this article</a> on AllPennyStocks.com.About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.
Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.
AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Contact:
AllPennyStocks.com Media, Inc.
Email: <a href="mailto:ads@allpennystocks.com">ads@allpennystocks.com</a>
Phone: (800) 558-4560 Ext: 101

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe...

OSR Holdings, Inc. operates as a global healthcare company. The firm engages in developing oral immunotherapies for cancer treatment, design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention of medical devices and systems distribution in Korea. Its products are offered through its subsidiaries. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA.

OSR Holdings Inc.

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Current Price	$0.4647
Prev Close	$0.4402
Open	$0.481
Dividend Yield	0.00%
50-Day Moving Average	$0.5202
Beta	0.56
Avg. Volume	480,037.15
PE Ratio	-0.23

52-Week High	$3.30
52-Week Low	$0.3803
Market Capitalization	$11.3M
EPS (Annual)	-$0.5379
Price to Book	0.13
Revenue Per Employee	$0.00

OSRH
OSR Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest OSRH News

OSRHOSR Holdings Inc